|  | WB-MRI protocol | Per-lesion analysis | Per-subject analysis | Cancer detection | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author | Year | Country | Magnet strenght | T1W TSE | T1W GE | T2W FS | T2W | DWI | Contrast | Cardiovascular sub-protocol | Classification method | All findings | Not relevant | ≥ Relevant | Highly relevant | n° of WB-MRI examinations | Entirely normal (no findings) | Abnormal findings reported | With relevant findings (requiring further evaluation) | Suspected malignant cancers | Confirmed malignant cancers | ||||||||
Goehde37 | 2005 | GER | 1.5 | Â | WB | Â | S | S | Y | cardiac, WB-MRA | binary: 1 (non-relevant), 2 (relevant) | 329 | 233 | 70,8% | 96 | 29,2% | Â | 298 | Â | Â | Â | Â | 82 | 31.0% | 1 | 0,3% | 1 | 0.3% | |
Baumgart38 | 2007 | GER | 1.5 |  | WB |  | S |  | Y | cardiac, WB-MRA | – |  |  |  |  |  |  | 1007 |  |  |  |  |  |  | 4 | 0,4% | 4 | 0.4% | |
Lo41 | 2008 | HKG | 3.0 | Â | WB | S | WB | Â | Â | Â | binary: 1 (non-relevant), 2 (relevant) | 234 | 210 | 89,7% | 24 | 10,3% | Â | 132 | 8 | 6,1% | 124 | 93,9% | 24 | 18.2% | 4 | 3,0% | 4 | 3.0% | |
Takahara42 | 2008 | NED | 1.5 |  | WB |  | WB | WB |  |  | – |  |  |  |  |  |  |  | 10 |  |  |  |  | 1 | 10.0% | 1 | 10,0% | 1 | 10.0% |
Hegenscheid43 | 2013 | GER | 1.5 | Â | WB | WB | S | S | optional | cardiac, WB-MRA | categorical system: 1(non-relevant), 2 (relevant benign), 3 (relevant unclear), 4 (relevant malignant) | 13,455 | 12,403 | 92,2% | 990 | 7,4% | 62 | 0,5% | 2500 | Â | Â | Â | Â | 787 | 31.5% | 62 | 2,5% | Â | Â |
Cieszanowski44 | 2014 | PLN | 1.5 | Â | WB | WB | Â | Â | Â | Â | categorical system: 1 (non-relevant), 2 (moderately or potentially relevant), 3 (relevant) | 3375 | 2997 | 88,8% | 378 | 11,2% | 15 | 0,4% | 666 | 7 | 1,1% | 659 | 98,9% | Â | Â | 7 | 1,1% | 7 | 1.1% |
Tarnoki45 | 2015 | GER | 3.0 | WB | WB | WB | Â | WB | Y | WB-MRA | categorical system: 1 (non-relevant), 2 (requiring further evaluation), 3 (relevant) | 68 | 44 | 64,7% | 24 | 35,3% | 1 | 1,5% | 22 | 2 | 9,1% | 20 | 90,9% | 15 | 68.0% | 1 | 4,5% | Â | Â |
Ulus46 | 2016 | TUR | 1.5 |  |  | WB | WB | S | optional |  | – |  |  |  |  |  |  | 116 | 33 | 28,4% | 83 | 71,6% | 12 | 10.3% | 3 | 2,6% | 2 | 1.7% | |
Saya47 | 2017 | UK | 1.5 | Â | WB | WB | Â | WB | Â | Â | categorical system: 1 (definitely benign), 2 (likely to be benign), 3 (equivocal), 4 (likely to be malignant), 5 (definitely malignant) | Â | Â | Â | Â | Â | Â | 44 | Â | Â | Â | Â | 8 | 18.2% | 0 | 0,0% | 0 | 0% | |
Lee48 | 2018 | KOR | 1.5 | Â | WB | WB | Â | Â | Â | Â | categorical system: 1 (benign), 2 (requiring further evaluation), 3 (malignant) | 500 | 290 | 58,0% | 210 | 42,0% | 6 | 1,2% | 229 | 16 | 7,0% | 213 | 93,0% | Â | Â | 6 | 2,6% | 2 | 0.9% |
Perkins*39 | 2018 | USA | 3.0 |  | WB |  | WB | WB | N | cardiac | – |  |  |  |  |  |  |  | 209* |  |  |  |  | 70 | 33.5% | 4 | 1,9% | 4* | 1.9% |
Hou40 | 2020 | USA | 3.0 |  | WB |  | WB | WB | N | cardiac | – |  |  |  |  |  |  |  | 1190 |  |  |  |  |  |  |  |  | 20 | 1.7% |
Total | Â | 17,961 | 16,336 | 91,0% | 1625 | 9,0% | 84 | 0.5% | 6214 | 66 / 1165 | 5,7% | 1099 / 1165 | 94,3% | 999 / 3331 | 30,0% | 93 / 5233 1.8% | 41 / 3692 1.1% |